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SUMMARY: Neuroendocrine differentiation in prostate carcinoma:
focusing on its pathophysiologic mechanisms and pathological fea-
tures.
C. ALBERTI
Prostate carcinoma, even at advanced stages, responds in most pa-
tients to androgen deprivation therapies, that are able to exploit the an-
drogen-sensitivity of prostate cancer cells. However, more than half of
such tumors, within one to three years, escape these treatments, thus
progressing to the hormone-refractory condition. Intriguing links
between the development of hormone-insensitivity and neuroendocrine
(NE) differentiation in prostate carcinoma have been hypothesized.
While, some time ago, NE cells have been considered as derived from
progenitor neural crest cells, currently are thought to arise, as well as
both basal and secretory cells of prostate gland, from common pluripo-
tent stem cells. NE cell are nonproliferative, terminally differentiated,
PSA/acid phosphatase and androgen receptor (AR)-negative cells, mo-
reover exhibiting an antiapoptotic phenotype due to survivin expres-
sion. They secrete a wide range of peptide hormones and biogenic ami-
ne serotonin and express neuronal markers such as chromogranins A, B,
C (CgA, B, C) and neuron specific enolase (NSE) together with synap-
tophysin. The propensity of prostate cancer cells to undergo a transdif-
ferentiation pathway towards NE phenotype is due to several microen-
vironmental conditions such as androgen depletion (induced by LH-
RH analogs or antagonists, antiandrogens, 5-α-reductase inhibitors),
ionizing-radiation therapy, adrenergic factors, increase in interleukin-
6 signaling cascade. NE differentiation in prostate malignancy arises in
three different forms: carcinoid, oat cell carcinoma, focally NE-diffe-
rentiated conventional tumor. Selective expression of stem cell-associa-
ted markers, such as CD44/Oct4A gene, in NE cancerous cells explain
their therapy escape together with tumor recurrence and metastasis.
Malignant NE cells, although unable to proliferate, increase the proli-
feration of the neighboring nonneuroendocrine cancer cells, by provi-
ding them with hormone peptide-mediated growth paracrine stimuli.
Aberrantly activated glutamic acid decarboxylase-independent
pathway for production of GABA (γ-amino-butyric acid) appears to be
a constant feature of invasive NE tumors. Serum levels of CgA reflect
NE differentiation in prostate carcinoma more suitably than those of
NSE. Intriguingly, intermittent androgen deprivation therapy, by pre-
venting NE differentiation, significantly reduces the risk of a rise in se-
rum CgA levels meanwhile delaying the time of cancer progression due
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Il carcinoma della prostata, pur negli stadi avanzati, è responsivo,
nella maggior parte dei malati, alle terapie di deprivazione androgeni-
ca basate sulla androgeno-dipendenza delle cellule tumorali prostati-
che. Tuttavia, più della metà di tali tumori, nell'intervallo da uno a tre
anni, elude l'efficacia di queste terapie, progredendo, pertanto, alla
condizione di ormono-refrattarietà. Sono state ipotizzate interessanti
correlazioni tra lo sviluppo dell'ormono-insensibilità e la comparsa di
differenziazione neuroendocrina (NE) nel carcinoma prostatico. Men-
tre fino a qualche anno fa, le cellule NE erano considerate come ele-
menti di derivazione dalle cellule progenitrici della cresta neurale, at-
tualmente sono ritenute trarre origine, alla stregua delle cellule basali e
secretorie ghiandolari prostatiche, da comuni cellule staminali pluripo-
tenti. Le cellule NE sono caratterizzate dall'essere non proliferative ed
in fase di differenziazione terminale, prive di recettori per gli androge-
ni (AR-negative), non produttrici di PSA e fosfatasi acida, presentan-
do, inoltre, un fenotipo antiapoptotico dovuto alla espressione di survi-
vina. Tali cellule secernono un ampio spettro di ormoni peptidici e la
serotonina, esprimendo, nel contempo, marcatori neuronali quali le
cromogranine A, B, C (CgA, B, C) e la enolasi neurono-specifica
(NSE) assieme alla sinaptofisina. La tendenza delle cellule neoplastiche
prostatiche a transdifferenziarsi nel fenotipo NE è riferibile a diverse
condizioni microambientali quali la deplezione di androgeni (indotta
da agonisti o antagonisti LH-RH, antiandrogeni, inibitori della 5-α-
reduttasi), trattamenti radianti, fattori adrenergici, accentuazione del-
la cascata di segnali dipendenti dalla interleuchina-6. La differenzia-
zione NE nella patologia tumorale prostatica si presenta in tre forme
differenti: carcinoide, oat cell carcinoma, tumore convenzionale con fo-
ci di differenziazione NE. L'espressione selettiva di marcatori proprî
delle cellule staminali, come il gene CD44/Oct4A, nelle cellule neopla-
stiche NE è atta a spiegare l'insensibilità alle terapie adottate nonché le
recidive e la metastatizzazione. Le cellule tumorali NE, quantunque
incapaci di proliferare, incrementano la proliferazione delle circostanti
cellule maligne non-NE, stimolandone, con modalità paracrine, la cre-
scita mediante gli ormoni peptidici. Costante caratteristica dei tumori
NE invasivi sembra essere l'aberrante attivazione del percorso metabo-
lico, decarbossilasi-indipendente, da acido glutammico a GABA (aci-
do γ-amino-butirrico). I livelli sierici di CgA riflettono la differenzia-
zione NE nel carcinoma prostatico in modo più attendibile rispetto a
quelli della NSE. Desta interesse la constatazione che la terapia abla-
tiva degli androgeni, di tipo intermittente, prevenendo la differenzia-
zione NE e ritardando, nel contempo, la progressione del tumore verso
l'ormono-refrattarietà, riduce la possibilità d'incremento sierico della
CgA. Sebbene significative acquisizioni conoscitive sulla natura della
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Prostate cancer neuroendocrine differentiation
In an oversimplified clinical framework of prostate ma-
lignancy, the disease evolves through a linear sequence of
conditions that include primary localized tumor, recur-
rence after primary treatment, cancer progression with hor-
mone-sensitive state followed by that refractory (1). In-
deed prostate carcinoma, even at advanced stages, responds,
with a response rate more that 80% of cases, to androgen
ablation therapies, involving LH-RH agonists or antagonists
and anti-androgens, which are able to exploit the andro-
gen-sensitivity of prostate cancer cells by either lowering
serum androgen levels or blocking androgen receptor (AR)
activity, hence inducing a massive apoptotic cancer cell
death (1-8). Nevertheless, more than half of such tumors,
within 15 to 36 months, escape these treatments, thus pro-
gressing to a hormone-refractory condition meanwhile the
prostate cancer cell population tending to be enriched with
neuroendocrine (NE) cells (4, 9-11). 
Intriguing links between NE differentiation and de-
velopment of hormone-insensitivity, with rising tumor
progression, in prostate malignancy, have been hy-
pothesized. 
Neuroendocrine cells: morphologic
features and functional behaviour 
Besides basal and secretory cells, NE cells are the
third epithelial cell type of the prostate gland, specifi-
cally sharing morhological and functional characteri-
stics with neurons present in normal prostatic tissue 2,
8. While, some time ago, they have been considered as
derived from progenitor neural crest cells, currently are
thought to arise, as well as both basal and secretory cel-
ls, from common pluripotent stem cells, representing,
in normal adult prostate gland, a minor epithelial cell
population (less than 1%), with greater density in the
periurethral ducts than in peripheral zone of the
gland (7, 8, 11, 12). Morphologically, there are two NE
cell types, a) open flask-shaped cells with apical exten-
sions towards the glandular lumen, and b), closed cel-
ls without luminal extensions. Both types show dendrite-
like cellular processes that may evoke a connection
network with adjacent epithelial cells (6-8, 12). Mo-
reover, NE cells may interact, in a paracrine fashion,
with prostate stromal tissue. Dense core granules are
specific features of NE cells, acting as storage of en-
dogenous secretory products. 
NE cells are postmitotic, nonproliferative, terminally
and highly differentiated, PSA/ acid phosphatase and
AR-negative cells, exhibiting an anti-apoptotic phe-
notype due to survivin expression while Bcl-2 negati-
ve (6, 13, 14). Functionally, prostate NE cells display
hybrid epithelial-neuro-endocrine features, with dual pro-
perties of endocrine cells and neurons, by secreting a
wide range of eutopic-orthotopic peptides, including cal-
citonin family peptides (calcitonin, calcitonin-gene-
related peptide, katacalcin), neurotensin, bombesin, thy-
roid stimulating-like peptide, parathyroid hormone-
related peptide, somatostatin, biogenic amine seroto-
nin (5-hydroxytryptamine, 5-HT) and by expressing
a number of neuronal markers such as neuron-specific
enolase (NSE), synaptophysin and chromogranins
(A, B and C-secretogranin). These secretory products
can act by endocrine, paracrine, autocrine mechanisms,
besides the open cell-related lumencrine way. It has been
hypothesized that NE cells might be involved in the re-
gulation of growth and differentiation of the develo-
ping prostate tissue and in modulating secretory acti-
vity in mature gland where some hormone peptides (e.g.,
calcitonin gene-related peptide, bombesin) and biogenic
amine serotonin have growth factor-mitogen activity
whereas others perform neurosecretory inhibitory
functions (e.g., somatostatin) (12). Particularly, so-
matostatin is able to block cell secretion and to inhi-
bit cell proliferation by inducing cell cycle arrest and
apoptosis; furthermore, it opposes the secretion of pi-
tuitary growth hormone (GH) with following reduc-
tion in IGF-1 (insulin growth factor-1) release from both
the liver and prostatic tissue (6, 7, 11-14).
Pathophysiology of neuroendocrine
differentiation in prostate carcinoma 
The propensity of prostate cancer cells to undergo
a transdifferentiation pathway towards NE phenotype
differenziazione NE nel carcinoma prostatico siano state raggiunte nel-
le ultime decadi, è necessario pervenire ad una più ampia comprensio-
ne dei suoi meccanismi patogenetici al fine di individuare strategie te-
rapeutiche innovative volte ad interferirvi in modo mirato.
to hormone-independence. Although valuable insights into the nature
of NE differentiation in prostate carcinoma have been achieved in the
last decades, additional understanding is needed about its pathogenetic
mechanisms in order to devise novel therapy strategies to target them.
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has been highlighted and has been related to several cell
growth/microenvironment conditions (Table 1):
— androgen depletion: androgen -deprivated me-
dium induces NE transdifferentiation of androgen-
sensitive LNCaP cells through a considerable increa-
se in cell cAMP concentrations (8, 15, 16). Intriguingly,
long-term culture of LNCaP cells in androgen-free se-
rum or in medium enriched with either cAMP or NS-
398 can induce proto-cadherin-PC gene over-expression
that coincides with their NE transdifferentiation to-
gether with acquisition of apoptosis resistance (8, 17).
Even more, short interfering RNAS directed against AR
to induce AR knockdown are able to activate NE tran-
sdifferentiation process in androgen sensitive LNCaP
cell lines by increasing their levels of NSE, cytoskele-
tal β-tubulin III and GAFP (glial acidic fibrillary pro-
tein) (5, 18). 
The expression of adrenomedullin (AM) — a 52-ami-
noacid peptide, calcitonin gene-related peptide ho-
mologue — markedly increases in LNCaP cells cultu-
red in androgen-depleted medium, meanwhile indu-
cing them to assume the NE phenotype (19, 20).
Furthemore, CD10-neutral endopeptidase 24.11 — cell
surface enzyme expressed by prostate epithelial cells and
physiologically activated by androgens to cleave neu-
ropeptide products of NE cells — is downregulated in
androgen withdrawal state, it resulting in an increase
in prostate levels of neuropeptides, such as bombesin
and endothelin-1, that are able to sustain prostate can-
cer growth and invasiveness (14, 21). 
Also a chronically maintened androgen-deprivation
condition (supplementation by dual 5-α-reductase inhi-
bitor dutasteride) could result in a rise of androgen-
indipendent LNCaP cell clones, expressing a NE phe-
notype (8, 22). Finasteride, that reduces intracellular
dihydrotestosterone levels by inhibiting 5-α-
reductase type-2, has been recognized as a suitable che-
mopreventive drug of prostate carcinoma, decreasing
its prevalence by about 25% (PCPT, prostate cancer pre-
vention trial), otherwise together with more than a
twofold raise in high grade invasive prostate carcino-
mas in finasteride-treated groups when compared to
controls; however, recent investigations seem point out
that finasteride may increase the rate of aggressive tu-
mors in CgA-positive (elevated CgA serum values)
subjects only if its continuous treatment is applied but
not in intermittent therapy (six months therapy and as
many resting period) (23, 24); 
— ionizing radiation therapy, resulting in an increase
of nuclear content of phospho-CREB (cyclic AMP-re-
sponse element binding protein) and in a cytoplasmic
accumulation of ATF 2 (activating transcription fac-
tor 2), both conditions that can induce NE-differen-
tiation, thus representing a novel mechanism by whi-
ch prostate malignant cells survive the radiation the-
rapy and may support cancer recurrence (25);
— long-term anticancer chemotherapy (docetaxel),
stress-induced by anticancer drugs playing a role in NE
differentiation similarly to castration therapy (3, 14, 52);
— prolonged treatment with adrenergic agents: indeed,
epinephrine and isoproterenol can induce NE diffe-
rentiation of LNCaP cell lines by increasing intra-cell
cAMP levels (16);
— exposure to factors that are able to promote IL-6
(interleukin-6) signaling cascade. In LNCaP cell line, the
treatment with IL-6 induces NE-like differentiation
whereas addition of androgens is able to block IL-6-
mediated PI3K (phosphatidylinositol-3-kinase) signa-
ling pathway and NE differentiation. As well as PI3K-
mediated pathway, IL-6 can promote NE differentia-
tion by activating other mechanisms such STAT-3 (si-
gnal transducer and activator of transcription) and
MAPKS (mitogen activated protein kinases)-dependent
signaling transductions (6, 26, 27).
The acquisition of NE features occurs gradually un-
der the influences of the microenvironmental conditions.
Indeed, all aforesaid pathogenetic conditions (andro-
gen depletion, adrenergic agents, ionizing radiation, fac-
tors activating IL-6 signaling pathway) are able to pro-
mote, through an increase in cell cAMP levels, the ex-
pression of several neuronal transcription factors (e.g.,
some members of Forkhead box-a, Foxa, that correla-
te with synaptophysin expression; Neuro Dl, a neuro-
nal differentiation factor; Brn-3a, a upregulating fac-
tor of voltage-gated Na+ channel expression in prosta-
te cancer cells) that lead a progressive transdifferentiation
of prostate cancer cells towards the NE-like phenoty-
pe (8, 28).
TABLE 1 - PROSTATE CANCER NEUROENDOCRINE DIFFERENTIATION: SOME ETIOPATHOGENETIC CONDITIONS.
• Androgen depletion: surgical or chemical androgen deprivation (LH-RH agonists or antagonists, antiandrogens, 5-α-reductase
inhibitors)
• Ionizing radiation therapy
• Long-term anticancer chemotherapy (docetaxel)
• Adrenergic agents (epinephrine, isoproterenol)
• Conditions activating IL-6 signaling cascade
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Pathological features
NE differentiation is more frequent in prostate car-
cinoma than in other genito-urinary malignancies and
it arises in three different forms: carcinoid or carcinoid-
like tumor, small cell (oat cell) carcinoma, focally NE-
differentiated conventional prostate carcinoma. Parti-
cularly, prostate carcinoid is poorly differentiated neo-
plasia which displays a wide NE differentiation; pro-
state small cell carcinoma is an undifferentiated, ex-
tremely aggressive tumor with rapid progression and me-
tastasis similarly to bronchogenic oat cell tumor; focal
NE differentiation is present, as clusters of malignant
NE cells, in virtually all cases of conventional prosta-
te carcinoma (29, 30).
Malignant NE cells of prostate carcinoma are phe-
notypically similar to normal prostate NE cells — po-
stmitotic, terminally differentiated, apoptosis inhibi-
ting (survivin), AR-negative and therefore surviving to
androgen deprivation, PSA-nonsecretive, chromogra-
nin/NSE/synaptophysin-positive cells — only differing
from them because of sharing tumor morphological cha-
racteristics with neighboring non-neuroendocrine can-
cerous cells (31, 32).
Selective expression of stem cell-associated marker
CD44 in NE cancerous cells may support the signifi-
cance of their therapy escape and of the tumor recur-
rence. Both Oct4A (splice variant of Oct3/4 gene) and
hASH1 (human achaete-scute homolog l), that is a pi-
votal member of Notch pathway, are markedly co-ex-
pressed with CgA in NE tumor cell populations (Ta-
ble 2) (33, 35).
Malignant NE cells, although unable to prolifera-
te, enhance the Ki-67 (proliferation index) positivity
of surrounding non-NE cancer cells by providing them
with paracrine growth stimuli such as bombesin, cal-
citonin gene- and parathormone-related peptides,
neurotensin, serotonin, so that, in most androgen-in-
dependent prostate carcinomas, non-NE cancer cells,
that express the anti-apoptotic Bcl-2 protooncogene,
are often localized in close proximity to NE neoplastic
cells. Also interleukin-8 (IL-8), which is produced by
NE tumor cells, is able to promote, by a paracrine me-
chanism, the proliferation of surrounding non-NE can-
cer cells (8, 12, 16, 36).
Moreover, neuropeptides released by NE cancerous
cells, besides facilitating the development of androgen
independence, are able to paradoxically reactivate
AR
S although in drug-induced androgen ablation sta-
te (5, 37). In an elegant animal model, it has been shown
that prostate cancer cells, under the influence of NE
cell products, can escape androgen deprivation therapy
and, what’s more, that the implantation of mouse NE-
prostate carcinoma in the flank of castrated nude mice
promotes the growth of human prostate tumor cell line
implanted in the opposite flank (38).
Otherwise, an aberrantly activated glutamic acid de-
carboxylase-independent pathway for production of
GABA (γ-amino-butyric acid) and an abnormal dopa-
decarboxylase membrane-associated amine oxidase-
dependent process for production of imidazole-4-
acetate, appear to be a constant feature of strongly in-
vasive NE tumors, that may be identified, as meaning
a poor prognosis, by molecular imaging modalities such
as MR-spectroscopy and PET (8, 39). 
Immunohistochemical studies show a NE tumor cell
immunoreactivity for both neuroendocrine markers
(CgA, NSE, synaptophysin) and neuropeptide hor-
mones together with biogenic amine serotonin (32). Pro-
state cancer tissue CgA is associated with a more quick
PSA progression time in patients under androgen-de-
privation therapy (40).
Serum levels of CgA reflect NE differentiation more
suitably than NSE, particularly using them during the
follow-up of advanced prostate carcinoma when PSA
lacks in value, although in poorly differentiated pro-
state tumors CgB might be the major component of
cancerous NE cells (6, 12, 31, 40-46). Intriguingly, it
TABLE 2 - MALIGNANT NEUROENDOCRINE CELLS: MORPHOLOGIC AND FUNCTIONAL FEATURES.
• Morphology — phenotypically similar to normal prostate NE cells (nonmitotic, terminally differentiated, AR-negative 
and therefore androgen-insensitive, PSA-nonsecretive, chromogranin A, B, C/synaptophysin/NSE 
positive), only sharing tumor morphologic characteristics with neighboring nonneuroendocrine 
cancer cells;
— selective expression of stem-cell-associated markers such as Oct4A gene.
• Fuction — although unable to proliferate, they enhance the proliferation of surrounding nonneuroendocrine 
malignant cells by peptide hormone-related growth paracrine stimuli;
— exert an antiapoptotic influence, by the survivin, on the neighboring nonneuroendocrine tumor cells;
— neuropeptides released by NE cancerous cells, besides facilitating the development of androgen 
independence, are able to aberrantly re-activate androgen receptors of prostate tumor although 
in androgen-deprivated state;
— interleukins (particularly IL-8), produced by NE cancerous cells, increase the invasiveness 
of prostate carcinoma.
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has been shown that intermittent androgen-ablation the-
rapy significantly reduces the risk of a rise in serum CgA
levels, by preventing NE differentiation of prostate can-
cer cells and delaying the time to cancer progression due
to castration therapy resistance (44).
Hypersecretion of either aforesaid eutopic or ecto-
pic (α- and β-chorionic gonadotropins, endorphins,
enkephalins, ACTH, ecc.) peptide hormones, especially
in patients with small cell carcinoma or primary car-
cinoid of the prostate, can sometimes induce paraneo-
plastic syndromes, such as, most frequently, those due
to inappropriate secretion of parathyroid hormone-
related peptide, ACTH and andidiuretic hormone (47).
Unlike most NE peptide products, the somatostatin has
anti-secretive and anti-cell growth effects, so that
some somatostatin analogs (octreotide, lanreotide, va-
preotide, SOM230), by directly targeting specific so-
matostatin receptors, may be used as inhibitors of can-
cer growth (3, 12, 48-51). Furthermore, the significant
expression of somatostatin type-2 receptors in NE-dif-
ferentiated prostate tumor, allows the receptor scinti-
graphy by means of 111In-pentatreotide, a somatosta-
tin analogue, of the primary prostate cancer and its me-
tastases, more specifically than 18F-fluoro-2-
deoxyglucose PET (49). Even, peptide receptor ra-
dionuclide therapy — biotherapy simultaneously with
selective irradiation — of either carcinoid or small cell
prostate tumors and their metastases, by using soma-
tostatin analogues 90Y-DOTATOC (DOTA-Tyr-
octreotide) and, more recently, 177Lu-DOTATATE
(DOTA-Tyr-octreotate), could be carried out as well
as it occurs in the therapy of gastro-entero-
pancreatic NE-tumors (50).
Emerging remarks and forecast 
for major research advances
In the last decades, NE differentiation in prostate
carcinoma has received more and more attention with
reference to its dramatic implications in prostate can-
cer progression and metastasis (2, 4, 6, 8, 11, 12, 30).
Therefore pathological features of NE prostate tumor
phenotype have been recognized as a crucial objective
for basal research by US-National Cancer Institute (6,
7 , 14).
Accumulate knowledge on this subject suggests that
the prostate cancer microenvironment is strongly dyna-
mic, also undergoing influences of exogenous condi-
tions (e.g., androgen ablation, radiation-therapy) that
can exert a selective pressure on the neoplastic cells. In-
deed, some etiopathogenetic factors of NE differen-
tiation of prostate cancer cells have been highlighted
— including androgen deprivation, ionizing radiations,
prolonged administration of adrenergic agents and stress
conditions, long-term anticancer chemotherapy, chronic
exposure to IL-6 —, anyway NE phenotype expression
representing an early marker associated with the de-
velopment of hormone independence (15-28, 52).
NE cancer cell products, as hormone peptides and bio-
genic amine serotonin, increase the proliferation index
of neighboring non-neuroendocrine cancer cells
meanwhile playing an antiapoptotic role by production
of survivin (13, 14, 36, 42, 54). Furthermore, NE dif-
ferentiation is implicated in chemoresistance induced
by EGF (Epidermal Growth Factor) in prostate mali-
gnant cells (53).
CgA appears to be a more suitable NE marker than
NSE, by detecting NE phenotype either at prostate tis-
sue level or in plasma, and has clinical usefulness in pre-
dicting the extent of NE differentiation in prostate car-
cinoma (29, 30, 44, 45, 54, 55). Interestingly, the in-
termittent androgen ablation therapy, by preventing for
a while the prostate cancer NE differentiation, delays
the increase in CgA serum levels (44). 
A potential role of general endocrine immunohi-
stochemical markers, in both well- and poorly-diffe-
rentiated neuroendocrine tumors of different sites, has
been recently suggested, even though with certain re-
servation, for histidine decarboxylase (HDC) and ve-
sicular monoamine transporter 2 (vMAT2), that are in-
volved in the byosynthesis and storage of histamine (56).
Because the NE differentiation of tumors is still re-
latively known pathological entity, the discrimination
of the true malignant NE pattern from that of an un-
differentiated tumor requires a proper qualification in
identifying NE-related biochemical alterations, moreover
resorting to molecular techniques (57, 59). In this way,
recent observations show that increase in Wnt (Win-
gless gene, Drosophila + Int-1, murine protoonconge-
ne) -11 levels in prostate carcinoma facilitate the NE
differentiation with tumor recurrence, such events pro-
ving to be prevented, on the contrary, by silencing Wnt-
11 expression in androgen-deprivated LNCaP cells (60).
Although valuable insights into the nature of NE
differentiation in prostate malignancy have been achie-
ved by recent studies, additional understanding is nee-
ded about it to provide novel treatment strategies di-
rected to target NE differentiation-related mechanisms
in patients with advanced hormone-refractory prosta-
te tumor (15-28, 52, 54, 61-65). Intriguingly, just on
this subject, it has been recently shown that exposure
of androgen-independent highly undifferentiated pro-
state cancer cells to nevirapine, a reverse transcriptase
inhibitor, is able to induce their conversion into a more
differentiated phenotype with AR signaling restoration
and following reappearance of hormone-sensitivity con-
dition, what could, in turn, interfere with NE diffe-
rentiation in prostate carcinoma (66).
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